JOP20220227A1 - مركبات بيرولو بيريميدين أمينات كمثبطات للمُتَمِّمِة - Google Patents

مركبات بيرولو بيريميدين أمينات كمثبطات للمُتَمِّمِة

Info

Publication number
JOP20220227A1
JOP20220227A1 JOP/2022/0227A JOP20220227A JOP20220227A1 JO P20220227 A1 JOP20220227 A1 JO P20220227A1 JO P20220227 A JOP20220227 A JO P20220227A JO P20220227 A1 JOP20220227 A1 JO P20220227A1
Authority
JO
Jordan
Prior art keywords
pyrrolopyrimidine
amines
complement inhibitors
compounds
complement system
Prior art date
Application number
JOP/2022/0227A
Other languages
English (en)
Inventor
Yarlagadda S Babu
zhao Dang
Krishnan Raman
Pravin L Kotian
Trung Xuan Nguyen
Minwan Wu
Original Assignee
Biocryst Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocryst Pharm Inc filed Critical Biocryst Pharm Inc
Publication of JOP20220227A1 publication Critical patent/JOP20220227A1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

يتعلق الاختراع الحالي بالكشف عن مركبات يكون لها الصيغة (I)، وأملاح مقبولة صيدليًا منها، وتكون عبارة عن مثبطات للجملة المُتَمِّمَة. كما يتم توفير تركيبات صيدلية تشتمل على مركب، وطرق لاستخدام المركبات والتركيبات في علاج أو منع مرض يتميز أو حالة تتميز بنشاط شاذ للجملة المُتَمِّمَة. (I).
JOP/2022/0227A 2020-04-03 2021-04-02 مركبات بيرولو بيريميدين أمينات كمثبطات للمُتَمِّمِة JOP20220227A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063004799P 2020-04-03 2020-04-03
PCT/US2021/025547 WO2021202977A1 (en) 2020-04-03 2021-04-02 Pyrrolopyrimidine amines as complement inhibitors

Publications (1)

Publication Number Publication Date
JOP20220227A1 true JOP20220227A1 (ar) 2023-01-30

Family

ID=77929437

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2022/0227A JOP20220227A1 (ar) 2020-04-03 2021-04-02 مركبات بيرولو بيريميدين أمينات كمثبطات للمُتَمِّمِة

Country Status (22)

Country Link
US (1) US20230159536A1 (ar)
EP (1) EP4125914A1 (ar)
JP (1) JP2023519824A (ar)
KR (1) KR20220163955A (ar)
CN (1) CN115427044A (ar)
AR (1) AR121715A1 (ar)
AU (1) AU2021246098A1 (ar)
BR (1) BR112022018067A2 (ar)
CA (1) CA3176808A1 (ar)
CL (1) CL2022002649A1 (ar)
CO (1) CO2022015630A2 (ar)
CR (1) CR20220553A (ar)
CU (1) CU20220060A7 (ar)
DO (1) DOP2022000211A (ar)
EC (1) ECSP22085221A (ar)
IL (1) IL296978A (ar)
JO (1) JOP20220227A1 (ar)
MX (1) MX2022012056A (ar)
PE (1) PE20230601A1 (ar)
TW (1) TW202204358A (ar)
UY (1) UY39150A (ar)
WO (1) WO2021202977A1 (ar)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023069301A1 (en) * 2021-10-18 2023-04-27 Alexion Pharmaceuticals, Inc. Use of complement factor d inhibitor for treatment of lupus nephritis and immunoglobulin a nephropathy
WO2024008121A1 (zh) * 2022-07-06 2024-01-11 南京明德新药研发有限公司 二氟取代的氮杂双环化合物及其应用
WO2024047078A1 (en) * 2022-09-01 2024-03-07 F. Hoffmann-La Roche Ag Dosage regimen of vicasinabin
US11945818B1 (en) 2023-09-06 2024-04-02 King Faisal University Pyrrolo[3,2-c]quinoline compounds as CK2 inhibitors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20140471A1 (es) * 2011-01-04 2014-04-13 Novartis Ag Moduladores de la via del complemento y usos de los mismos

Also Published As

Publication number Publication date
US20230159536A1 (en) 2023-05-25
ECSP22085221A (es) 2022-12-30
CO2022015630A2 (es) 2022-11-29
DOP2022000211A (es) 2022-11-15
UY39150A (es) 2021-10-29
CR20220553A (es) 2023-02-03
WO2021202977A1 (en) 2021-10-07
JP2023519824A (ja) 2023-05-15
CN115427044A (zh) 2022-12-02
CA3176808A1 (en) 2021-10-07
MX2022012056A (es) 2022-10-13
KR20220163955A (ko) 2022-12-12
TW202204358A (zh) 2022-02-01
CL2022002649A1 (es) 2023-05-26
BR112022018067A2 (pt) 2022-10-25
AR121715A1 (es) 2022-06-29
AU2021246098A1 (en) 2022-10-20
IL296978A (en) 2022-12-01
EP4125914A1 (en) 2023-02-08
PE20230601A1 (es) 2023-04-10
CU20220060A7 (es) 2023-05-11

Similar Documents

Publication Publication Date Title
MX2022007915A (es) Compuestos de benzopirazol y analogos de estos.
MX2022012056A (es) Pirrolopirimidinaminas como inhibidores del sistema del complemento.
PH12021551529A1 (en) 3-carbonylamino-5-cyclopentyl-1h-pyrazole compounds having inhibitory activity on cdk2
MX2023007192A (es) Inhibidores de prmt5.
PH12018500147A1 (en) Benzodiazepine derivatives as rsv inhibitors
MX2022010011A (es) Inhibidores de prmt5 novedosos.
JOP20220075A1 (ar) مثبطات عامل d المكمل عن طريق الفم
MX2022014817A (es) Benzofurano, benzopirrol, benzotiofeno sustituidos y otros inhibidores del complemento estructuralmente relacionados.
MX2022004264A (es) Inhibidores del factor d del complemento para administracion oral.
MX2021015854A (es) Composiciones y métodos para tratar trastornos del snc.
MX2022004450A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1.
MX2022009197A (es) Metodos de tratamiento para deficiencia de alfa-1 antitripsina.
SA519410865B1 (ar) مركب حلقي شبيه بكُومارين بوصفه مثبط mek واستخدامه
MX2021012105A (es) Compuestos de pirrol.
MX2021011144A (es) Derivados de las benzodiazepinas como inhibidores del vsr.
MX2021014372A (es) Compuestos derivados de 1,3,4-oxadiazol como inhibidores de histona desacetilasa 6, y la composicion farmaceutica que comprende los mismos.
MX2022009898A (es) Compuesto de dihidronaftiridinona y metodo de preparacion del mismo y uso medico del mismo.
WO2021133894A8 (en) Btk inhibitors
MY160963A (en) Sustained-release therapeutic agent for hypertension and renal dysfunction
MX2022008487A (es) Degradadores de smarca2-vhl.
BR112021025618A2 (pt) Composto, método para prevenir, tratar ou diminuir a gravidade de uma doença, composição farmacêutica e uso de um composto
WO2020096916A3 (en) Inhibitors of histone deacetylase useful for the treatment or prevention of hiv infection
EA202192511A1 (ru) Бензодиазепиновые производные в качестве ингибиторов рсв
PH12021550093A1 (en) Compounds for use in the treatment of fascioliasis
ZA202204251B (en) Compounds and compositions for the treatment of parasitic diseases